Climate change is recognised as the biggest public health crisis of our time.1 The World Health Organization (WHO) estimates that air pollution alone causes seven million premature deaths each year and heat-related deaths are expected to treble by 2050.1,2
慢性呼吸道疾病 are prime examples of the growing health impacts of climate change. Poor air quality and extreme weather conditions pose great risks to people living with asthma and chronic obstructive pulmonary disease (COPD) and increase the number of people developing these diseases.2
With all medicines and healthcare interactions contributing to greenhouse gas (GHG) emissions,3 everyone in the delivery of healthcare has a role to play in decarbonising health systems. 事实上，医疗保健的气候足迹是4.4% of the global total; meaning if it were a country, 它将成为地球上第五大排放国.4
Improving patient outcomes and reducing the carbon footprint of respiratory care
在澳门在线赌城娱乐, l work with a team dedicated to discovering and developing respiratory medicines that improve outcomes for patients, while being deeply committed to lowering the environmental burden of respiratory care. 慢性呼吸道疾病, 包括哮喘和慢性阻塞性肺病, 是复杂的, 难治性疾病难以治疗且经常控制不良的, 哪个与更高的碳足迹有关.3 这种碳足迹源于药物的使用, doctor visits and hospital care – the time patients spend in hospital being a major driver of healthcare emissions.5 With nearly 550 million people globally living with respiratory diseases and prevalence rising, 潜在的相关碳足迹是显著的.6
早期检测, diagnosis and disease control to avoid exacerbations are therefore some of the most powerful ways to reduce overall healthcare resource utilisation and hospitalisations, 护理的碳足迹也是如此.3 Adoption of evidence-based treatment strategies and guideline implementation that prioritises respiratory disease control and reduces exacerbations is critical to achieving this; this also presents a solution to decision-makers seeking to decarbonise healthcare.
提供不同的呼吸护理
同时努力改善患者的治疗效果, another key element to decarbonising respiratory care is the transition to climate-friendly inhaled medicines. 这些药物, 包括加压计量吸入器(pmdi), 全球呼吸系统患者的基本选择是什么.7,8,9
而pmdi的贡献小于0.占全球温室气体排放量的1%，3 尽管如此，澳门第一赌城在线娱乐认为显著减轻这一负担至关重要. In fact, 在澳门在线赌城娱乐, work to reduce the carbon footprint of our pMDIs is already underway and represents an important step towards achieving our 零碳雄心 goal.10
We are accelerating the development of our next-generation respiratory inhalers using a propellant with near-zero Global Warming Potential10 (类似于干粉吸入器), 这也是非持久性的(在环境中很容易分解))11 而且是非生物累积性的12 (不会在生物体内累积). A practical transition to climate-friendly propellants is important to ensure continuity of patient care and maintain access to essential medicines that can be life-saving. 这些药物预计将于2025年首次上市，13 在制定任何气候政策时都应考虑这些因素.
Overall, 政府间合作, policymakers and the global respiratory community will be key to delivering sustainable and life-saving healthcare practices in respiratory care, 哪些继续满足病人, 公共卫生和环境需要.
你可能也喜欢
References
1. WHO. 气候变化与健康. [Online]. 可从http://www上读取。.who.int /新闻/说明书/细节/气候变化与健康问题. [2023年8月生效]
2. WHO. 环境(室外)空气污染. [Online]. 可在:http://www.who.int/news-room/fact-sheets/detail/ambient-(outdoor)-air-quality-and-health. [2023年8月生效]
3. 威尔金森一. et al. Greenhouse gas emissions associated with asthma care in the UK: results from SABINA CARBON. Oral session presented at the 10th International Primary Care 呼吸 Group (IPCRG) World Conference, 2021 May 6-8; Dublin, Ireland.
4. ARUP. 医疗保健的气候足迹. [Online]. 可在:http://www.arup.com/perspectives/publications/research/section/healthcares-climate-footprint. [2023年8月生效]
5. SMI. 使病人护理途径脱碳. [Online]. 可在:http://a.storyblok.com/f/109506/x/88fe7ea368/smi-hstf-pcp-whitepaper.pdf. [2023年8月生效]
6. Wu Y et al. 前线公共卫生. Global Burden of 呼吸 Diseases Attributable to Ambient Particulate Matter Pollution: Findings From the Global Burden of Disease Study 2019. 2021;9: doi: 10.3389/fpubh.2021.
7. Usmani OS，等. Real-world impact of non-clinical inhaler regimen switches on asthma or COPD: a systematic review. 杰克:在练习中. 2022:10(10);2625-2637.
8. Doyle S，等. What happens to patients who have their asthma device switched without their consent? Prim Care呼吸器. 2010; 19 (2): 131–139.
9. Bjermer L. The Importance of continuity in inhaler device choice for asthma and chronic obstructive pulmonary. 呼吸. 2014;88(4):346-52.
10. 澳门在线赌城娱乐. 澳门在线赌城娱乐 progresses 零碳雄心 programme with Honeywell partnership to develop next- generation respiratory inhalers. Available at: 澳门在线赌城娱乐 progresses 零碳雄心 programme with Honeywell partnership to develop next-generation respiratory inhalers. [2023年8月生效]
11. Wallington TJ, Sulbaek Andersen MP, Nielsen OJ. Atmospheric chemistry of short-chain haloolefins: photochemical ozone creation potentials (POCPs), 全球变暖潜能值, 及臭氧消耗潜能值. 光化层. 2015;129:135-141.
12. ECHA档案- 1-丙烯，1,3,3,3-四氟-. 可在:http://echa.europa.欧盟/注册档案/ - /注册档案/ 31292/2/3. [2023年8月生效]
13. A Study to Assess How Much Drug Reaches the Blood When Given From Symbicort pMDI With Spacer Compared to That of Symbicort pMDI Without Spacer in Healthy Volunteers. 可在:http://clinicaltrials.gov / ct2 /显示/ NCT02934607. [2023年8月生效]
Veeva ID: Z4-59297
筹备日期:2023年10月